chromomycin-a3 and Neoplasm-Metastasis

A study was made of the relationship between post-operative chemotherapy and metastasis and recurrence of bladder tumor in 9 patients with renal pelvic and ureteral tumors. Within 6 months on average, post-operative metastasis was found in 33.3% (3 out of 9 cases). Differentiating according to the type of chemotherapy, the rate of occurrence of metastasis was 50% (2 out of 4) in the case of treatment with either a combination of FT-207, chromomycin A3 and cytosine arabinoside, or with FT-207 alone, while it was 100% (2 out of 2) in stage pT2 and pT3 patients. For combined administration of CDDP, FT-207 and cytosine arabinoside, or for that of CDDP and neocarzinostatin, on the other hand, the rate of occurrence of metastasis was only 20% (1 out of 5) in stage pT2 and pT3 patients, while CDDP administration was found to be effective for preventing post-operative metastasis. However, while recurrence of bladder tumor was found in a total of 3 out of 9 cases (33.3%), recurrence occurred in 40% (2 out of 5) of the cases treated with CDDP. The administration of CDDP was therefore not found to be effective for preventing recurrence of bladder tumor.

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromomycin A3; Cisplatin; Cytarabine; Humans; Infusions, Parenteral; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Neoplasm Metastasis; Postoperative Care; Tegafur; Ureteral Neoplasms; Urinary Bladder; Urinary Bladder Neoplasms

Chromomycin A3 was administered iv to 26 patients in a phase I trial. The maximum tolerated dose established in this study was 0.75 mg/m2/day iv X 5 days. The drug was then given to 48 evaluable patients with far-advanced disseminated breast cancer. Two short partial remissions and one clinical improvement were seen. Toxic manifestations consisted of frequent and usually reversible renal toxicity, nausea and vomiting, occasional thrombocytopenia, hypocalcemia, and two instances of semicoma. Drug toxicity may have contributed to the death of two patients.

Topics: Breast Neoplasms; Chromomycin A3; Chromomycins; Drug Evaluation; Female; Humans; Hypocalcemia; Kidney; Nausea; Neoplasm Metastasis; Remission, Spontaneous; Vomiting

Topics: Anti-Bacterial Agents; Chromomycin A3; Cyclophosphamide; Esophageal Neoplasms; Geriatrics; Laryngeal Neoplasms; Laryngectomy; Maxillary Neoplasms; Mesenchymoma; Neoplasm Metastasis; Neoplasms; Otolaryngology; Surgical Procedures, Operative; Tongue Neoplasms; Tonsillar Neoplasms